XELLIA PHARMACEUTICALS ApS: Financial statements 2017
CVR: 61094628
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2017. In 2017, the company reported revenue of DKK 1,897,063,000 and a net result of DKK 91,002,000 compared with DKK 33,769,000 the year before. That is an increase of 28.6% compared with the year before. The profit margin was 4.8%. Equity in the 2017 report amounted to DKK 850,770,000. The solvency ratio was 33.7%. The company had 493 employees in the financial year.
- Revenue
- DKK 1,897,063,000
- Gross Profit
- DKK 528,294,000
- Profit/Loss
- DKK 91,002,000
- Equity
- DKK 850,770,000
- Total Assets
- DKK 2,521,355,000
- Employees
- 493
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 1.9B | 528.3M | 91M | 850.8M | 493 |
| 2016 | 1.5B | 521.8M | 33.8M | 758.8M | 466 |
| 2015 | 1.2B | 364.2M | -74M | 729.2M | 479 |
Official annual report
Keep an eye on XELLIA PHARMACEUTICALS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of December 7, 2017, Lennart Bo Fredmark has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of December 7, 2017, Lone Finner has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of December 7, 2017, Jan Høgh Bergmann has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of December 6, 2017, Lennart Bo Fredmark has left the board of directors of XELLIA PHARMACEUTICALS ApS.
XELLIA PHARMACEUTICALS ApS has published its annual report for 2016. Revenue came to DKK 1,475,168,000, and the net result was DKK 33,769,000.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.